MedTrace Logo

NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH

NCT02998905 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-20

No results posted yet for this study

Summary

To determine the feasibility of a controlled trial examining the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) compared with ASA for stroke prevention in patients with a high-risk of atrial fibrillation and previous intracerebral hemorrhage.

Conditions

Interventions

DRUG

NOAC

Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.

DRUG

Acetylsalicylic Acid

Acetylsalicylic acid 81 mg/day

Sponsors & Collaborators

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Ashkan Shoamanesh, MD FRCPC · Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-26
Primary Completion
2019-10-31
Completion
2020-02-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998905 on ClinicalTrials.gov